title: Akt signalling in health and disease.
abstract: Akt (also known as protein kinase B or PKB) comprises three closely related isoforms Akt1, Akt2 and Akt3 (or PKBα/β/γ respectively). We have a very good understanding of the mechanisms by which Akt isoforms are activated by growth factors and other extracellular stimuli as well as by oncogenic mutations in key upstream regulatory proteins including Ras, PI3-kinase subunits and PTEN. There are also an ever increasing number of Akt substrates being identified that play a role in the regulation of the diverse array of biological effects of activated Akt; this includes the regulation of cell proliferation, survival and metabolism. Dysregulation of Akt leads to diseases of major unmet medical need such as cancer, diabetes, cardiovascular and neurological diseases. As a result there has been substantial investment in the development of small molecular Akt inhibitors that act competitively with ATP or phospholipid binding, or allosterically. In this review we will briefly discuss our current understanding of how Akt isoforms are regulated, the substrate proteins they phosphorylate and how this integrates with the role of Akt in disease. We will furthermore discuss the types of Akt inhibitors that have been developed and are in clinical trials for human cancer, as well as speculate on potential on-target toxicities, such as disturbances of heart and vascular function, metabolism, memory and mood, which should be monitored very carefully during clinical trial.
authors.affiliation: School of Physiology and Pharmacology, University of Bristol, UK.
authors.forename: Ingeborg
authors.initials: I
authors.lastname: Hers
authors.forename: Emma E
authors.initials: EE
authors.lastname: Vincent
authors.forename: Jeremy M
authors.initials: JM
authors.lastname: Tavaré
mesh_terms: D001665:Binding Sites; D002318:Cardiovascular Diseases / Q000201:enzymology / Q000378:metabolism; D049109:Cell Proliferation; D003920:Diabetes Mellitus / Q000201:enzymology / Q000378:metabolism; D004789:Enzyme Activation; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D015394:Molecular Structure; D009369:Neoplasms / Q000201:enzymology / Q000378:metabolism; D009422:Nervous System Diseases / Q000201:enzymology / Q000378:metabolism; D010069:Oxadiazoles / Q000494:pharmacology; D010766:Phosphorylation; D020033:Protein Isoforms / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000145:classification* / Q000494:pharmacology; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015398:Signal Transduction; D014157:Transcription Factors / Q000378:metabolism
chemical_list: C528328:GSK690693; D010069:Oxadiazoles; D020033:Protein Isoforms; D047428:Protein Kinase Inhibitors; D014157:Transcription Factors; D051057:Proto-Oncogene Proteins c-akt